Ensysce Biosciences, Inc.
ENSC
$2.17
-$0.30-12.15%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 5.21M | 4.42M | 1.44M | 1.75M | 2.23M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.21M | 4.42M | 1.44M | 1.75M | 2.23M |
| Cost of Revenue | 7.22M | 5.65M | 5.87M | 6.57M | 7.59M |
| Gross Profit | -2.01M | -1.23M | -4.44M | -4.82M | -5.36M |
| SG&A Expenses | 4.72M | 5.08M | 5.23M | 5.18M | 5.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.94M | 10.73M | 11.10M | 11.75M | 12.95M |
| Operating Income | -6.73M | -6.31M | -9.66M | -10.00M | -10.72M |
| Income Before Tax | -7.99M | -7.93M | -11.28M | -11.55M | -10.63M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.99 | -7.93 | -11.28 | -11.55 | -10.63 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 100.00 | 1.10K | 2.30K | 9.40K | 13.20K |
| Net Income | -7.99M | -7.93M | -11.28M | -11.54M | -10.61M |
| EBIT | -6.73M | -6.31M | -9.66M | -10.00M | -10.72M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -13.45 | -27.50 | -41.58 | -52.98 | -76.02 |
| Normalized Basic EPS | -8.41 | -17.19 | -25.98 | -33.07 | -48.68 |
| EPS Diluted | -13.45 | -27.50 | -41.58 | -52.98 | -76.02 |
| Normalized Diluted EPS | -8.41 | -17.19 | -25.98 | -33.07 | -48.68 |
| Average Basic Shares Outstanding | 2.86M | 1.83M | 1.38M | 943.60K | 634.30K |
| Average Diluted Shares Outstanding | 2.86M | 1.83M | 1.38M | 943.60K | 634.30K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |